Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EGFRt/19-28z/IL-12 CAR-T cells |
| Synonyms | |
| Therapy Description |
EGFRt/19-28z/IL-12 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to CD3zeta and CD28 signaling domains, truncated EGFR, and the cytokine IL-12, which potentially induce cytotoxicity against CD19-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EGFRt/19-28z/IL-12 CAR-T cells | EGFRt/19-28z/IL-12 CAR T cells | CD19 Immune Cell Therapy 72 | EGFRt/19-28z/IL-12 CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 linked to CD3zeta and CD28 signaling domains, truncated EGFR, and the cytokine IL-12, which potentially induce cytotoxicity against CD19-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Terminated | USA | 0 |